Compare BHR & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHR | NPCE |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.6M | 514.3M |
| IPO Year | N/A | 2021 |
| Metric | BHR | NPCE |
|---|---|---|
| Price | $2.84 | $15.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 786.3K | 189.2K |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | ★ 6.99% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $710,399,000.00 | $94,864,000.00 |
| Revenue This Year | N/A | $24.82 |
| Revenue Next Year | N/A | $0.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $1.80 | $7.56 |
| 52 Week High | $3.28 | $18.98 |
| Indicator | BHR | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 54.60 | 45.71 |
| Support Level | $2.77 | $15.29 |
| Resistance Level | $2.98 | $16.33 |
| Average True Range (ATR) | 0.11 | 0.54 |
| MACD | 0.00 | -0.27 |
| Stochastic Oscillator | 63.03 | 5.77 |
Braemar Hotels & Resorts Inc is a real estate investment trust company that invests in high revenue per available room, or RevPAR, luxury, upper-upscale and upscale hotels in gateway and resort locations. The firm operates in various U.S. states such as California, Texas, Washington, Philadelphia, Florida, and Illinois as well as Washington, D.C. and St. Thomas, U.S. Virgin Islands. The company operates through its direct hotel investment segment of the hotel lodging industry. Its revenue streams include rooms, food and beverage, and other. The firm's hotels operate under various brands, such as Marriott, Hilton, Courtyard, and, among others.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.